Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
53 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 12
Calgary, Alberta, Canada
- Arcutis Clinical Site 09
Surrey, British Columbia, Canada
- Arcutis Clinical Site 26
Winnipeg, Manitoba, Canada
- Arcutis Clinical Site 20
Ajax, Ontario, Canada
- Arcutis Clinical Site 23
London, Ontario, Canada
- Arcutis Clinical Site 25
Toronto, Ontario, Canada
- Arcutis Clinical Site 16
Waterloo, Ontario, Canada
- Arcutis Clinical Site 08
Drummondville, Quebec, Canada
- Arcutis Clinical Site 27
Québec, Quebec, Canada
- Arcutis Clinical Site 31
Birmingham, Alabama, United States
- Arcutis Clinical Site 51
Fort Smith, Arkansas, United States
- Arcutis Clinical Site 46
Inglewood, California, United States
- Arcutis Clinical Site 19
San Diego, California, United States
- Arcutis Clinical Site 36
San Diego, California, United States
- Arcutis Clinical Site 13
Santa Monica, California, United States
- Arcutis Clinical Site 54
Centennial, Colorado, United States
- Arcutis Clinical Site 55
Boca Raton, Florida, United States
- Arcutis Clinical Site 30
Coral Gables, Florida, United States
- Arcutis Clinical Site 37
Delray Beach, Florida, United States
- Arcutis Clinical Site 41
Miami, Florida, United States
- Arcutis Clinical Site 58
Miami, Florida, United States
- Arcutis Clinical Site 11
Sanford, Florida, United States
- Arcutis Clinical Site 57
West Palm Beach, Florida, United States
- Arcutis Clinical Site 62
Boise, Idaho, United States
- Clinical Site 04
Plainfield, Indiana, United States
- Arcutis Clinical Site 43
Louisville, Kentucky, United States
- Arcutis Clinical Site 63
Baton Rouge, Louisiana, United States
- Arcutis Clinical Site 42
Lake Charles, Louisiana, United States
- Arcutis Clinical Site 38
Mandeville, Louisiana, United States
- Arcutis Clinical Site 06
Metairie, Louisiana, United States
- Arcutis Clinical Site 34
Rockville, Maryland, United States
- Arcutis Clinical Site 29
Clinton Township, Michigan, United States
- Arcutis Clinical Site 21
Fort Gratiot, Michigan, United States
- Arcutis Clinical Site 61
Troy, Michigan, United States
- Arcutis Clinical Site 245
Saint Joseph, Missouri, United States
- Arcutis Clinical Site 53
New York, New York, United States
- Arcutis Clinical Site 39
Rochester, New York, United States
- Arcutis Clinical Site 33
Stony Brook, New York, United States
- Arcutis Clinical Site 01
High Point, North Carolina, United States
- Arcutis Clinical Site 24
Hershey, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Feb 2021
- Primary completion
- 29 Sept 2022
- Completion
- 29 Sept 2022
- Last update posted
- 4 Oct 2024
- Registered enrollment
- 683
- Registry id
- NCT04773600
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.